Analytical Data
-
Gene name
ROR1
- Application
-
Alternative Names
NTRKR1; Tyrosine-protein kinase transmembrane receptor ROR1; Neurotrophic tyrosine kinase, receptor-related 1
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Z139
-
Expression Region
Leu470~Lys707
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ROR1 (Receptor tyrosine kinase-like orphan receptor 1) is a protein predominantly expressed during embryonic development and is associated with various malignancies, including several types of cancer such as breast cancer, leukemia, and non-small cell lung cancer. Its expression in adult tissues is minimal, making it an attractive target for cancer immunotherapy. Recognized for its role in signaling pathways that control cell survival, proliferation, and differentiation, ROR1's re-emergence in cancer cells suggests a potential for tumor progression. Research into ROR1 has focused on the development of ROR1-targeted therapies, including monoclonal antibodies and CAR T-cell therapy, which aim to selectively eradicate cancer cells while sparing normal cells. The study of recombinant ROR1 proteins is pivotal in understanding its structure-function relationship and interactions with downstream signaling pathways. Such investigations not only elucidate the biological functions of ROR1 but also pave the way for novel therapeutic strategies, ultimately enhancing the efficacy and specificity of cancer treatments.
